LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova director Francesco Bianchi sold 1,500 ordinary shares on 08/25/2025 at a reported price of $56.50 per share. After the sale he beneficially owned 9,028 ordinary shares, reported as direct ownership. The Form 4 was signed on behalf of the reporting person by Sarah K. Mohr, Attorney-in-Fact, on 08/27/2025. The filing discloses the transaction code S (sale) and provides the reporter's London address; no derivative transactions or amendments are reported.
LivaNova PLC (LIVN) submitted a Form 144 notice reporting a proposed sale of 1,500 ordinary shares through Merrill Lynch with an aggregate market value of $84,750. The shares were acquired on 06/29/2021 upon vesting of a restricted stock unit award granted under the issuer's equity compensation plan. The filer indicates the approximate date of sale as 08/25/2025 and the intended exchange is NASDAQ. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer and references Rule 144 and Rule 10b5-1 trading plan considerations.
LivaNova PLC (LIVN) Q2-25 10-Q highlights:
- Net revenue rose 10.6% YoY to $352.5 m; six-month revenue up 9.1% to $669.4 m.
- Gross margin held steady at 67.8%; operating income jumped 34.9% to $54.2 m on disciplined SG&A (+10.1%) and R&D spend (-7.9%).
- GAAP EPS improved to $0.50 versus $0.30; diluted share count 54.7 m.
- Six-month results swung to a $300.2 m loss after booking a $362.1 m SNIA environmental charge.
- Cash climbed to $593.6 m (-$130 m q-o-q after releasing $294.7 m restricted cash); total debt reduced 31% to $430.6 m following a $200 m early term-loan repayment.
- SNIA litigation reserve now $392.3 m; €270 m surety bond in place pending appeal. Cyber-incident costs reached $13 m, with $9.6 m insurance recovery to date.
- Liquidity: $225 m revolver undrawn; operating cash flow +63% YoY to $86.9 m H1-25.
- No covenant breaches; capped-call and embedded derivatives re-measured, neutral P&L effect.
Management reaffirmed focus on core Cardiopulmonary & Neuromodulation segments and continues restructuring begun 2024. Litigation and environmental exposures remain the key overhang despite solid operating momentum and deleveraging.